Show simple item record

dc.contributor.authorBizzotto, R
dc.contributor.authorJennison, C
dc.contributor.authorJones, AG
dc.contributor.authorKurbasic, A
dc.contributor.authorTura, A
dc.contributor.authorKennedy, G
dc.contributor.authorBell, JD
dc.contributor.authorThomas, EL
dc.contributor.authorFrost, G
dc.contributor.authorEriksen, R
dc.contributor.authorKoivula, RW
dc.contributor.authorBrage, S
dc.contributor.authorKaye, J
dc.contributor.authorHattersley, AT
dc.contributor.authorHeggie, A
dc.contributor.authorMcEvoy, D
dc.contributor.author't Hart, LM
dc.contributor.authorBeulens, JW
dc.contributor.authorElders, P
dc.contributor.authorMusholt, PB
dc.contributor.authorRidderstråle, M
dc.contributor.authorHansen, TH
dc.contributor.authorAllin, KH
dc.contributor.authorHansen, T
dc.contributor.authorVestergaard, H
dc.contributor.authorLundgaard, AT
dc.contributor.authorThomsen, HS
dc.contributor.authorDe Masi, F
dc.contributor.authorTsirigos, KD
dc.contributor.authorBrunak, S
dc.contributor.authorViñuela, A
dc.contributor.authorMahajan, A
dc.contributor.authorMcDonald, TJ
dc.contributor.authorKokkola, T
dc.contributor.authorForgie, IM
dc.contributor.authorGiordano, GN
dc.contributor.authorPavo, I
dc.contributor.authorRuetten, H
dc.contributor.authorDermitzakis, E
dc.contributor.authorMcCarthy, MI
dc.contributor.authorPedersen, O
dc.contributor.authorSchwenk, JM
dc.contributor.authorAdamski, J
dc.contributor.authorFranks, PW
dc.contributor.authorWalker, M
dc.contributor.authorPearson, ER
dc.contributor.authorMari, A
dc.date.accessioned2021-05-13T13:40:30Z
dc.date.issued2020-12-15
dc.description.abstractOBJECTIVE: We investigated the processes underlying glycemic deterioration in type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: A total of 732 recently diagnosed patients with T2D from the Innovative Medicines Initiative Diabetes Research on Patient Stratification (IMI DIRECT) study were extensively phenotyped over 3 years, including measures of insulin sensitivity (OGIS), β-cell glucose sensitivity (GS), and insulin clearance (CLIm) from mixed meal tests, liver enzymes, lipid profiles, and baseline regional fat from MRI. The associations between the longitudinal metabolic patterns and HbA1c deterioration, adjusted for changes in BMI and in diabetes medications, were assessed via stepwise multivariable linear and logistic regression. RESULTS: Faster HbA1c progression was independently associated with faster deterioration of OGIS and GS and increasing CLIm; visceral or liver fat, HDL-cholesterol, and triglycerides had further independent, though weaker, roles (R2 = 0.38). A subgroup of patients with a markedly higher progression rate (fast progressors) was clearly distinguishable considering these variables only (discrimination capacity from area under the receiver operating characteristic = 0.94). The proportion of fast progressors was reduced from 56% to 8-10% in subgroups in which only one trait among OGIS, GS, and CLIm was relatively stable (odds ratios 0.07-0.09). T2D polygenic risk score and baseline pancreatic fat, glucagon-like peptide 1, glucagon, diet, and physical activity did not show an independent role. CONCLUSIONS: Deteriorating insulin sensitivity and β-cell function, increasing insulin clearance, high visceral or liver fat, and worsening of the lipid profile are the crucial factors mediating glycemic deterioration of patients with T2D in the initial phase of the disease. Stabilization of a single trait among insulin sensitivity, β-cell function, and insulin clearance may be relevant to prevent progression.en_GB
dc.description.sponsorshipNational Institute for Health Research (NIHR)en_GB
dc.description.sponsorshipInnovative Medicines Initiative Joint Undertakingen_GB
dc.description.sponsorshipEuropean Union FP7en_GB
dc.description.sponsorshipEuropean Federation of Pharmaceutical Industries and Associationsen_GB
dc.identifier.citationVol. 44 (2), pp. 511 - 518en_GB
dc.identifier.doi10.2337/dc20-1567
dc.identifier.grantnumber115317en_GB
dc.identifier.urihttp://hdl.handle.net/10871/125659
dc.language.isoenen_GB
dc.publisherAmerican Diabetes Associationen_GB
dc.rights© 2020 by the American Diabetes Associationen_GB
dc.titleProcesses Underlying Glycemic Deterioration in Type 2 Diabetes: An IMI DIRECT Studyen_GB
dc.typeArticleen_GB
dc.date.available2021-05-13T13:40:30Z
dc.descriptionThis is the author accepted manuscript. The final version is available from the American Diabetes Association via the DOI in this recorden_GB
dc.identifier.eissn1935-5548
dc.identifier.journalDiabetes Careen_GB
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_GB
dcterms.dateAccepted2020-10-31
exeter.funder::National Institute for Health Research (NIHR)en_GB
rioxxterms.versionAMen_GB
rioxxterms.licenseref.startdate2020-12-15
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2021-05-13T10:48:59Z
refterms.versionFCDAM
refterms.dateFOA2021-05-13T13:41:08Z
refterms.panelAen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record